The Dow Jones closed lower by around 80 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.
Stereotaxis
- The Trade: Stereotaxis, Inc. STXS Director Paul J Isaac acquired a total of 2,808 shares an average price of $1.56. To acquire these shares, it cost around $4,380.
- What’s Happening: On Nov. 9, Stereotaxis posted downbeat quarterly results.
- What Stereotaxis Does: Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures.
Retractable Technologies
- The Trade: Retractable Technologies, Inc. RVP President and CEO Thomas J Shaw acquired a total of 1,595 shares at an average price of $1.13. To acquire these shares, it cost around $1,799.
- What’s Happening: On Nov. 14, Retractable Technologies reported that its loss from operations was $8.7 million for the first nine months of 2023.
- What Retractable Technologies Does: Retractable Technologies Inc designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession.
Check This Out: Campbell Soup, SentinelOne And 3 Stocks To Watch Heading Into Wednesday
VerifyMe
- The Trade: VerifyMe, Inc. VRME Director Marshall S Geller acquired a total of 1,100 shares at an average price of $1.04. The insider spent around $1,144 to buy those shares.
- What’s Happening: On Nov. 8, VerifyMe posted upbeat quarterly results.
- What VerifyMe Does: VerifyMe Inc is a technology solutions company based in the United States. It markets a broad patent portfolio that includes patents in the field of authenticating products, people, and financial transactions.
Eyenovia
- The Trade: Eyenovia, Inc. EYEN CEO Michael Rowe acquired a total of 4,890 shares at an average price of $1.36. The insider spent around $6,650 to buy those shares.
- What’s Happening: On Nov. 13, Eyenovia posted upbeat quarterly sales.
- What Eyenovia Does: Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology.
Don’t forget to check out our premarket coverage here
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.